Disclosures for "IVIg is Effective in Patient with Cyclophosphamide-Refractory Susac Syndrome "
-
Dr. Patel has nothing to disclose.
-
Dr. Offerle has nothing to disclose.
-
Dr. Lannen has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Genentech. Dr. Lannen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for TG Therapeutics. Dr. Lannen has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Horizon Theraputics.